Nitric Oxide-Donating Genistein Prodrug: Design, Synthesis, and Bioactivity on MC3T3-E1 Cells
-
- Wang Jiepin
- Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, China Institute of Materia Medica, School of Pharmacy, Fourth Military Medical University, China
-
- Shang Fujun
- Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, China
-
- Jiang Ru
- Department of Chemistry, School of Pharmacy, Fourth Military Medical University, China
-
- Liu Li
- Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, China
-
- Wang Siwang
- Institute of Materia Medica, School of Pharmacy, Fourth Military Medical University, China
-
- Hou Jin
- Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, China
-
- Huan Menglei
- Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, China
-
- Mei Qibing
- Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, China
この論文をさがす
抄録
To find a more potent alternative with less estrogen-related side effects for hormone replacement therapy, we designed and synthesized a nitric oxide (NO)-releasing prodrug of genistein, named NO-donating genistein (NO-G). The characteristics of NO-G were determined by melting point, NMR spectroscopy, and mass spectrometric analysis. HPLC has been used to test the new prodrug’s stability. The releasing capacity of NO-G was tested by Griess reagent in vitro. The bioactivities of NO-G on proliferation, differentiation, and mineralization of the osteoblastic cell line MC3T3-E1 were determined by MTT assay, flow cytometric analysis, measurement of the alkaline phosphatase (ALP) activity and the secreted osteocalcin (OCN), and Alizarin Red-S staining. The product showed 1H NMR spectra and relative molecular mass in agreement with the designed structure, and it was stable in buffer solution. NO-G continually released low level NO within 5 h in MC3T3-E1 cells. NO-G caused a significant elevation of cell growth, ALP activity, and OCN secretion in both dose- and time-dependent manner. Furthermore, the Alizarin Red-S staining showed that NO-G promoted mineralization of MC3T3-E1 cells. These effects were all significantly greater than those of its parent drugs. The results suggested that NO-G might be a novel drug for the treatment of postmenopausal osteoporosis.<br>
収録刊行物
-
- Journal of Pharmacological Sciences
-
Journal of Pharmacological Sciences 104 (1), 82-89, 2007
公益社団法人 日本薬理学会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390282680152264320
-
- NII論文ID
- 10024314089
-
- NII書誌ID
- AA11806667
-
- ISSN
- 13478648
- 13478613
-
- NDL書誌ID
- 8737756
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可